TUBB3 and cancer: To reduce the expression of TUBB3 and improve survival of cancer patients, several anti-microtubule chemotherapeutic agents (i.e. paclitaxel, capecitabine, carboplatin) were suggested and the studies demonstrated that the patients were more sensitive to these treatments when TUBB3 mRNA expression was low enough [31–34].